Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerseâ„¢ Immunotherapy in Recurrent Respiratory Papillomatosis

Author's Avatar
Jan 04, 2023

PR Newswire